{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:04:36Z","timestamp":1791489876698,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04372-y","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T01:57:36Z","timestamp":1754013456000},"page":"391-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antithyroid drugs and the dose\u2013risk balance: a meta-analysis on agranulocytosis in hyperthyroidism"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-1257","authenticated-orcid":false,"given":"Luis Agust\u00edn","family":"Ram\u00edrez Stieben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-2096","authenticated-orcid":false,"given":"Lucas Ricardo","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Nasazzi Doddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-9921","authenticated-orcid":false,"given":"Mar\u00eda Lorena","family":"Brance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"4372_CR1","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1210\/jc.2013-1954","volume":"98","author":"V Sundaresh","year":"2013","unstructured":"V. Sundaresh, J.P. Brito, Z. Wang, L.J. Prokop, M.N. Stan, M.H. Murad et al., Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 98, 3671\u20133677 (2013). https:\/\/doi.org\/10.1210\/jc.2013-1954.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4372_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/pds.4156","volume":"26","author":"C-W Sing","year":"2017","unstructured":"C.-W. Sing, I.C.K. Wong, B.M.Y. Cheung, J.C.Y. Chan, J.K.P. Chu, C.-L. Cheung, Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese: a population-based case-control study. Pharmacoepidemiol. Drug Saf. 26, 248\u2013255 (2017). https:\/\/doi.org\/10.1002\/pds.4156.","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4372_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/archinte.159.4.369","volume":"159","author":"MM van der Klauw","year":"1999","unstructured":"M.M. van der Klauw, R. Goudsmit, M.R. Halie, M.B. van\u2019t Veer, R.M. Herings, J.H. Wilson et al., A population-based case-cohort study of drug-associated agranulocytosis. Arch. Intern. Med. 159, 369\u2013374 (1999). https:\/\/doi.org\/10.1001\/archinte.159.4.369.","journal-title":"Arch. Intern. Med."},{"key":"4372_CR4","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1210\/jc.2013-2569","volume":"98","author":"H Nakamura","year":"2013","unstructured":"H. Nakamura, A. Miyauchi, N. Miyawaki, J. Imagawa, Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J. Clin. Endocrinol. Metab. 98, 4776\u20134783 (2013). https:\/\/doi.org\/10.1210\/jc.2013-2569.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4372_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/jcem-11-10-1057","volume":"11","author":"EC Bartels","year":"1951","unstructured":"E.C. Bartels, R.W. Sjogren, 1-Methyl-2-mercaptoimidazole: a new active antithyroid agent. J. Clin. Endocrinol. Metab. 11, 1057\u20131062 (1951). https:\/\/doi.org\/10.1210\/jcem-11-10-1057.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4372_CR6","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.4158\/EP11339.CR","volume":"18","author":"P Mutharasan","year":"2012","unstructured":"P. Mutharasan, W. Oatis, H. Kwaan, M. Molitch, Delayed antithyroid drug-induced agranulocytosis. Endocr. Pract. 18, e69\u2013e72 (2012). https:\/\/doi.org\/10.4158\/EP11339.CR.","journal-title":"Endocr. Pract."},{"issue":"2","key":"4372_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4158\/EP-2019-0221","volume":"26","author":"W Yu","year":"2020","unstructured":"W. Yu, N. Wu, L. Li, J. Wang, H. OuYang, H. Shen, Side effects of PTU and MMI in the treatment of hyperthyroidism: a systematic review and meta-analysis. Endocr. Pract. 26(2), 207\u2013217 (2020). https:\/\/doi.org\/10.4158\/EP-2019-0221.","journal-title":"Endocr. Pract."},{"key":"4372_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/archinte.150.3.621","volume":"150","author":"J Tajiri","year":"1990","unstructured":"J. Tajiri, S. Noguchi, T. Murakami, N. Murakami, Antithyroid drug-induced agranulocytosis: the usefulness of routine white blood cell count monitoring. Arch. Intern. Med. 150, 621\u2013624 (1990). https:\/\/doi.org\/10.1001\/archinte.150.3.621.","journal-title":"Arch. Intern. Med."},{"key":"4372_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1507\/endocrj.EJ24-0135","volume":"71","author":"J Yoshimura Noh","year":"2024","unstructured":"J. Yoshimura Noh, K. Inoue, N. Suzuki, A. Yoshihara, M. Fukushita, M. Matsumoto et al., Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil. Endocr. J. 71, 695\u2013703 (2024). https:\/\/doi.org\/10.1507\/endocrj.EJ24-0135.","journal-title":"Endocr. J."},{"key":"4372_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0002-9343(54)90141-2","volume":"17","author":"TH McGavack","year":"1954","unstructured":"T.H. McGavack, J. Chevalley, Untoward hematologic responses to the antithyroid compounds. Am. J. Med. 17, 36\u201340 (1954). https:\/\/doi.org\/10.1016\/0002-9343(54)90141-2.","journal-title":"Am. J. Med."},{"key":"4372_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/thy.2008.0364","volume":"19","author":"K Takata","year":"2009","unstructured":"K. Takata, S. Kubota, S. Fukata, T. Kudo, E. Nishihara, M. Ito et al., Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19, 559\u2013563 (2009). https:\/\/doi.org\/10.1089\/thy.2008.0364.","journal-title":"Thyroid"},{"key":"4372_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1365-2265.2012.04365.x","volume":"77","author":"F Otsuka","year":"2012","unstructured":"F. Otsuka, J.Y. Noh, T. Chino, T. Shimizu, K. Mukasa, K. Ito et al., Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin. Endocrinol. 77, 310\u2013315 (2012). https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04365.x.","journal-title":"Clin. Endocrinol."},{"key":"4372_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron et al., RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019). https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4372_CR14","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"J.A. Sterne, M.A. Hern\u00e1n, B.C. Reeves, J. Savovi\u0107, N.D. Berkman, M. Viswanathan et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919 (2016). https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"4372_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"M. Egger, G. Davey Smith, M. Schneider, C. Minder, Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634 (1997). https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"4372_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"S. Duval, R. Tweedie, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455\u2013463 (2000). https:\/\/doi.org\/10.1111\/j.0006-341x.2000.00455.x.","journal-title":"Biometrics"},{"key":"4372_CR17","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1210\/jcem.76.6.8501160","volume":"76","author":"D Reinwein","year":"1993","unstructured":"D. Reinwein, G. Benker, J.H. Lazarus, W.D. Alexander, A prospective randomized trial of antithyroid drug dose in Graves\u2019 disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J. Clin. Endocrinol. Metab. 76, 1516\u20131521 (1993). https:\/\/doi.org\/10.1210\/jcem.76.6.8501160.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4372_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/thy.2014.0084","volume":"25","author":"S Sato","year":"2015","unstructured":"S. Sato, J.Y. Noh, S. Sato, M. Suzuki, S. Yasuda, M. Matsumoto et al., Comparison of efficacy and adverse effects between methimazole 15 mg + inorganic iodine 38 mg\/day and methimazole 30 mg\/day as initial therapy for Graves\u2019 disease patients with moderate to severe hyperthyroidism. Thyroid 25, 43\u201350 (2015). https:\/\/doi.org\/10.1089\/thy.2014.0084.","journal-title":"Thyroid"},{"issue":"4","key":"4372_CR19","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.19193\/0393-6384_2020_4_344","volume":"36","author":"H Zhao","year":"2020","unstructured":"H. Zhao, N. Chu, J. Han, F. Wang, Effect of methimazole on serum TSAb and TBII levels in patients with Graves\u2019 hyperthyroidism. Acta Med. Mediterr. 36(4), 2207\u20132211 (2020). https:\/\/doi.org\/10.19193\/0393-6384_2020_4_344.","journal-title":"Acta Med. Mediterr."},{"key":"4372_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/00000441-198904000-00003","volume":"297","author":"MC Werner","year":"1989","unstructured":"M.C. Werner, J.H. Romaldini, N. Bromberg, R.S. Werner, C.S. Farah, Adverse effects related to thionamide drugs and their dose regimen. Am. J. Med. Sci. 297, 216\u2013219 (1989). https:\/\/doi.org\/10.1097\/00000441-198904000-00003.","journal-title":"Am. J. Med. Sci."},{"key":"4372_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1530\/EJE-13-0811","volume":"170","author":"E Mohlin","year":"2014","unstructured":"E. Mohlin, H. Filipsson Nystr\u00f6m, M. Eliasson, Long-term prognosis after medical treatment of Graves\u2019 disease in a northern Swedish population 2000\u20132010. Eur. J. Endocrinol. 170, 419\u2013427 (2014). https:\/\/doi.org\/10.1530\/EJE-13-0811.","journal-title":"Eur. J. Endocrinol."},{"key":"4372_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/thy.2015.0439","volume":"26","author":"J Yang","year":"2016","unstructured":"J. Yang, Y.-J. Zhu, J.-J. Zhong, J. Zhang, W.-W. Weng, Z.-F. Liu et al., Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid 26, 627\u2013633 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0439.","journal-title":"Thyroid"},{"key":"4372_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.14310\/horm.2002.11112","volume":"3","author":"F Aga\u00e7i","year":"2004","unstructured":"F. Aga\u00e7i, Clinical aspects of hyperthyroidism in hospitalised patients in Albania. Hormones 3, 53\u201358 (2004). https:\/\/doi.org\/10.14310\/horm.2002.11112.","journal-title":"Hormones"},{"key":"4372_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/105072504323150787","volume":"14","author":"J Tajiri","year":"2004","unstructured":"J. Tajiri, S. Noguchi, Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 14, 459\u2013462 (2004). https:\/\/doi.org\/10.1089\/105072504323150787.","journal-title":"Thyroid"},{"key":"4372_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1507\/endocrj.k05-068","volume":"54","author":"K Tsuboi","year":"2007","unstructured":"K. Tsuboi, H. Ueshiba, M. Shimojo, M. Ishikawa, N. Watanabe, K. Nagasawa et al., The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves\u2019 disease. Endocr. J. 54, 39\u201343 (2007). https:\/\/doi.org\/10.1507\/endocrj.k05-068.","journal-title":"Endocr. J."},{"key":"4372_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1210\/jcem-63-1-125","volume":"63","author":"A Shiroozu","year":"1986","unstructured":"A. Shiroozu, K. Okamura, H. Ikenoue, K. Sato, T. Nakashima, M. Yoshinari et al., Treatment of hyperthyroidism with a small single daily dose of methimazole. J. Clin. Endocrinol. Metab. 63, 125\u2013128 (1986). https:\/\/doi.org\/10.1210\/jcem-63-1-125.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4372_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1507\/endocrj.44.553","volume":"44","author":"Y Mashio","year":"1997","unstructured":"Y. Mashio, M. Beniko, A. Matsuda, S. Koizumi, K. Matsuya, H. Mizumoto et al., Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr. J. 44, 553\u2013558 (1997). https:\/\/doi.org\/10.1507\/endocrj.44.553.","journal-title":"Endocr. J."},{"key":"4372_CR28","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1210\/jcem.83.3.4613","volume":"83","author":"RS Rittmaster","year":"1998","unstructured":"R.S. Rittmaster, E.C. Abbott, R. Douglas, M.L. Givner, L. Lehmann, S. Reddy et al., Effect of methimazole, with or without L-thyroxine, on remission rates in Graves\u2019 disease. J. Clin. Endocrinol. Metab. 83, 814\u2013818 (1998). https:\/\/doi.org\/10.1210\/jcem.83.3.4613.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4372_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1530\/eje.1.01904","volume":"152","author":"F Azizi","year":"2005","unstructured":"F. Azizi, L. Ataie, M. Hedayati, Y. Mehrabi, F. Sheikholeslami, Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur. J. Endocrinol. 152, 695\u2013701 (2005). https:\/\/doi.org\/10.1530\/eje.1.01904.","journal-title":"Eur. J. Endocrinol."},{"key":"4372_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.curtheres.2008.08.004","volume":"69","author":"L Chen","year":"2008","unstructured":"L. Chen, H.-Q. Wang, Y.-Y. Gao, J. Liang, M. Wang, J. Bai et al., Comparison of methimazole\/hydrocortisone ointment with oral methimazole in patients with Graves disease: a prospective, randomized, open-label, parallel-group, 18-month study. Curr. Ther. Res. Clin. Exp. 69, 305\u2013317 (2008). https:\/\/doi.org\/10.1016\/j.curtheres.2008.08.004.","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"4372_CR31","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.etap.2013.09.015","volume":"36","author":"X Wu","year":"2013","unstructured":"X. Wu, H. Liu, X. Zhu, J. Shen, Y. Shi, Z. Liu et al., Efficacy and safety of methimazole ointment for patients with hyperthyroidism. Environ. Toxicol. Pharmacol. 36, 1109\u20131112 (2013). https:\/\/doi.org\/10.1016\/j.etap.2013.09.015.","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"4372_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1089\/thy.2018.0397","volume":"29","author":"F Azizi","year":"2019","unstructured":"F. Azizi, M. Takyar, E. Madreseh, A. Amouzegar, Treatment of toxic multinodular goiter: comparison of radioiodine and long-term methimazole treatment. Thyroid 29, 625\u2013630 (2019). https:\/\/doi.org\/10.1089\/thy.2018.0397.","journal-title":"Thyroid"},{"key":"4372_CR33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/thy.2020.0433","volume":"31","author":"F Azizi","year":"2021","unstructured":"F. Azizi, H. Abdi, L. Cheraghi, A. Amouzegar, Treatment of subclinical hyperthyroidism in the elderly: comparison of radioiodine and long-term methimazole treatment. Thyroid 31, 545\u2013551 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0433.","journal-title":"Thyroid"},{"key":"4372_CR34","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3803\/EnM.2022.1476","volume":"37","author":"F Azizi","year":"2022","unstructured":"F. Azizi, N. Saadat, M.A. Takyar, H. Abdi, L. Mehran, A. Amouzegar, Efficacy and safety of long-term methimazole versus radioactive iodine in the treatment of toxic multinodular goiter. Endocrinol. Metab. 37, 861\u2013869 (2022). https:\/\/doi.org\/10.3803\/EnM.2022.1476.","journal-title":"Endocrinol. Metab."},{"issue":"5","key":"4372_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1365-2265.1989.tb01424.x","volume":"30","author":"H Tamai","year":"1989","unstructured":"H. Tamai, Y. Takaichi, T. Morita, G. Komaki, S. Matsubayashi, K. Kuma, R.M. Walter Jr, L.F. Kumagai, S. Nagataki, Methimazole-induced agranulocytosis in Japanese patients with Graves\u2019 disease. Clin. Endocrinol. 30(5), 525\u2013530 (1989). https:\/\/doi.org\/10.1111\/j.1365-2265.1989.tb01424.x.","journal-title":"Clin. Endocrinol."},{"key":"4372_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF03344959","volume":"17","author":"M Meyer-Gessner","year":"1994","unstructured":"M. Meyer-Gessner, G. Benker, S. Lederbogen, T. Olbricht, D. Reinwein, Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J. Endocrinol. Invest. 17, 29\u201336 (1994). https:\/\/doi.org\/10.1007\/BF03344959.","journal-title":"J. Endocrinol. Invest."},{"key":"4372_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/qjmed\/92.8.455","volume":"92","author":"WH Sheng","year":"1999","unstructured":"W.H. Sheng, C.C. Hung, Y.C. Chen, C.T. Fang, S.M. Hsieh, S.C. Chang et al., Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. QJM 92, 455\u2013461 (1999). https:\/\/doi.org\/10.1093\/qjmed\/92.8.455.","journal-title":"QJM"},{"key":"4372_CR38","first-page":"242","volume":"30","author":"C-H Huang","year":"2007","unstructured":"C.-H. Huang, K.-L. Li, J.-H. Wu, P.-N. Wang, J.-H. Juang, Antithyroid drug-induced agranulocytosis: report of 13 cases. Chang Gung Med. J. 30, 242\u2013248 (2007).","journal-title":"Chang Gung Med. J."},{"key":"4372_CR39","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/BF03346433","volume":"31","author":"E Mazza","year":"2008","unstructured":"E. Mazza, M. Carlini, D. Flecchia, A. Blatto, O. Zuccarini, S. Gamba et al., Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with methimazole: comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses\u2014a retrospective study. J. Endocrinol. Invest. 31, 866\u2013872 (2008). https:\/\/doi.org\/10.1007\/BF03346433.","journal-title":"J. Endocrinol. Invest."},{"key":"4372_CR40","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1210\/jc.2011-2221","volume":"97","author":"N Watanabe","year":"2012","unstructured":"N. Watanabe, H. Narimatsu, J.Y. Noh, T. Yamaguchi, K. Kobayashi, M. Kami et al., Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves\u2019 disease. J. Clin. Endocrinol. Metab. 97, E49\u2013E53 (2012). https:\/\/doi.org\/10.1210\/jc.2011-2221.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4372_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/thy.2018.0274","volume":"29","author":"M Gershinsky","year":"2019","unstructured":"M. Gershinsky, W. Saliba, I. Lavi, C. Shapira, N. Gronich, Increased risk of antithyroid drug agranulocytosis associated with amiodarone-induced thyrotoxicosis: a population-based cohort study. Thyroid 29, 193\u2013201 (2019). https:\/\/doi.org\/10.1089\/thy.2018.0274.","journal-title":"Thyroid"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04372-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04372-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04372-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:09:44Z","timestamp":1761736184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04372-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4372"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04372-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}